About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Clinical Biochemistry, Drug Delivery & Therapy (CB-DDT) group arises from the merger of two VHIR groups, the Clinical Biochemistry group and the Drug Delivery and Targeting group, which they develop preclinical and clinical research in the diagnosis and therapy of different diseases.
With a direct link to the Clinical Biochemistry service of the Vall d'Hebron Hospital, our scope of action ranges from the analysis of massive data coming from the service, the development of diagnostic and prognostic biomarkers, evaluation of existing therapies and the development of new therapeutic strategies based on nanotechnology.
In terms of specific pathologies or indications, the group has an extensive track record in basic and applied research in cancer (new biomarkers, therapeutic targets and new treatments), metabolopathies (biomarkers and improvements in enzyme replacement therapy), kidney disease and liver disease.
PMID: 37183562 Journal: EUROPEAN JOURNAL OF NEUROLOGY Year: 2023 Reference: Eur J Neurol. 2023 May 14. doi: 10.1111/ene.15866. Impact factor: Publication type: Paper in international publication Authors: Chuquisana, Omar; Comabella, Manuel; Ferrer, Roser; Fissolo, Nicolas; Gil-Varea, Elia; Giralt, Marina; Lunemann, Jan D; Malhotra, Sunny; Midaglia, Luciana; Montalban, Xavier et al. DOI: 10.1111/ene.15866
PMID: 37073757 Journal: Nutricion Hospitalaria Year: 2023 Reference: Nutr Hosp. 2023 Apr 11. doi: 10.20960/nh.04436. Impact factor: Publication type: Paper in international publication Authors: Albertos, Raquel; Albertos, Raquel; Barquin, Raquel; Berlana, David; Cea, Cristina; Lopez-Hellin, Juan; Montoro-Ronsano, J Bruno; Pau-Parra, Alba; Zabalegui, Alba et al. DOI: 10.20960/nh.04436
PMID: 37833106 Journal: MEDICINA CLINICA Year: 2023 Reference: Med Clin (Barc). 2023 Oct 11:S0025-7753(23)00552-3. doi: 10.1016/j.medcli.2023.08.010. Impact factor: Publication type: Other (letters to the editor, abstracts, corrigendum, etc.) Authors: Andrade, Fernanda; Cardona, Victoria; Duran-Lara, Esteban F; Galvan-Blasco, Paula; Gil-Serrano, Johana; Lobos G, Olga; Rafael, Diana; Vijayakumar, Sekar et al. DOI: 10.1016/j.medcli.2023.08.010
PMID: 37952070 Journal: Internal and Emergency Medicine Year: 2023 Reference: Intern Emerg Med. 2023 Nov 11. doi: 10.1007/s11739-023-03441-2. Impact factor: Publication type: Paper in international publication Authors: Abrisqueta, Pau; Augustin, Salvador; Campo, Elias; Casanueva-Eliceiry, Sebastian; Ciudin, Andreea; Correa, Juan Gonzalo; Delgado, Julio; Ferrer-Costa, Roser; Gabriel-Medina, Pablo; Gine, Eva et al. DOI: 10.1007/s11739-023-03441-2
PMID: 34873314 Journal: Nature Reviews Nephrology Year: 2022 Reference: Nat Rev Nephrol. 2022 Feb;18(2):80-81. doi: 10.1038/s41581-021-00521-4. Impact factor: Publication type: Review in international publication Authors: Jacobs-Cacha, Conxita; Soler, Maria Jose et al. DOI: 10.1038/s41581-021-00521-4
PMID: 34758113 Journal: HEPATOLOGY Year: 2022 Reference: Hepatology. 2022 Feb;75(2):501-502. doi: 10.1002/hep.32227. Epub 2021 Dec 18. Impact factor: Publication type: Letter or abstract Authors: Buti, Maria; Cortese, Maria Francesca; Rando-Segura, Ariadna; Rodriguez-Frias, Francisco; Tabernero, David et al. DOI: 10.1002/hep.32227
PMID: 34998911 Journal: EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS Year: 2022 Reference: Eur J Pharm Biopharm. 2022 Feb;171:39-49. doi: 10.1016/j.ejpb.2021.10.017. Epub 2022 Jan 5. Impact factor: Publication type: Paper in international publication Authors: Arango, Diego; Colaco, Ariana; Fourniols, Thibaut; Garcia Vidal, Elia; Lopes, Alessandra; Maggio, Valentina; Martinez-Barriocanal, Agueda; Preat, Veronique; Rafael, Diana; Schwartz, Simo et al. DOI: 10.1016/j.ejpb.2021.10.017
PMID: 34842496 Journal: Emerging Microbes & Infections Year: 2022 Reference: Emerg Microbes Infect. 2022 Dec;11(1):172-181. doi: 10.1080/22221751.2021.2011617. Impact factor: Publication type: Paper in international publication Authors: Andres, Cristina; Anton, Andres; Blanco-Grau, Albert; Borras-Bermejo, Blanca; Campins-Marti, Magda; Campos, Carolina; Castillo, Carla; Codina, Maria Gema; Colomer-Castell, Sergi; Esperalba, Juliana et al. DOI: 10.1080/22221751.2021.2011617
PMID: 32896242 Journal: CLINICAL AND EXPERIMENTAL RHEUMATOLOGY Year: 2021 Reference: Clin Exp Rheumatol. 2021 Mar-Apr;39(2):337-343. Epub 2020 Sep 3. Impact factor: Publication type: Paper in international publication Authors: Barcelo, Mireia; De Agustin, Juan Jose; Ferrer, Roser; Julia, Antonio; Lopez-Corbeto, Mireia; Lopez-Lasanta, Maria; Marsal, Sara; Martinez-Mateu, Sergio; Pluma, Andrea et al. DOI:
PMID: 33803133 Journal: Cancers Year: 2021 Reference: Cancers (Basel). 2021 Mar 9;13(5). pii: cancers13051164. doi: 10.3390/cancers13051164. Impact factor: Publication type: Review in international publication Authors: Andrade, Fernanda; Duran-Lara, Esteban F; Rafael, Diana; Roca-Melendres, Maria Merce; Schwartz, Simo Jr et al. DOI: 10.3390/cancers13051164
PMID: 33800211 Journal: Diagnostics Year: 2021 Reference: Diagnostics (Basel). 2021 Mar 8;11(3). pii: diagnostics11030473. doi: 10.3390/diagnostics11030473. Impact factor: Publication type: Paper in international publication Authors: Buti, Maria; Esteban, Angels; Martinez-Camprecios, Joan; Najarro-Centeno, Adrian; Pumarola-Sune, Tomas; Quer, Josep; Rando-Segura, Ariadna; Rodriguez-Frias, Francisco; Salmeron, Paula; Velasquez-Orozco, Fernando et al. DOI: 10.3390/diagnostics11030473
PMID: 33811970 Journal: MOLECULAR AND CELLULAR ENDOCRINOLOGY Year: 2021 Reference: Mol Cell Endocrinol. 2021 Jun 1;529:111263. doi: 10.1016/j.mce.2021.111263. Epub 2021 Mar 31. Impact factor: Publication type: Paper in international publication Authors: Benito, Begona; Dominguez-Baez, Pamela; Garcia-Carro, Clara; Jacobs-Cacha, Conxita; Molina-Van den Bosch, Mireia; Seron, Daniel; Soler, Maria Jose; Vergara, Ander et al. DOI: 10.1016/j.mce.2021.111263
Based on the study led by VHIR, a clinical trial has been approved for patients with locally advanced pancreatic cancer.
Vall d'Hebron participates in a project to develop innovative microsampling technology, making blood collection more accessible and patient-centered.
Researchers from all over Europe gathered to kick off the SPM4.0 project, an innovative Marie Curie Skłodowska (MSCA-DN) doctoral network that promotes the development of autonomous Scanning Probe Microscopy with AI.
